Your hub to the latest Knowledge in Nuclear Medicine/Molecular Imaging
Press releases
Hermes Medical Solutions Receives 510(k) FDA Clearance for its Hermia NM Processing (Hybrid Viewer)
Hermes Medical Solutions (HMS), global market leader in molecular imaging and dosimetry software solutions receives 510(k) FDA Clearance for its Hybrid Viewer 7.0. The product has previously been CE-marked and holds a medical device license from Health Canada.
Witness the exciting Hermia news at the Hermes Medical Solutions booth at EANM 2024
Hermes Medical Solutions (HMS), global market leader in molecular imaging and dosimetry software solutions is excited to showcase all new and upcoming product updates to the All-in-One Molecular Imaging Software Suite Hermia at EANM 2024.
Hermia Dosimetry will be available on Siemens’ booth through syngo.via at EANM 2024
Hermes Medical Solutions (HMS), a leader in molecular imaging software development, and Siemens Healthineers, a global provider of healthcare equipment, solutions, and services, will demonstrate their partnership at this year’s EANM to provide Siemens Healthineers customers with access to Hermia dosimetry products.
Scientific publications
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Bone marrow toxicity in advanced prostate cancer patients who receive [Lu-177]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [Lu-177]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference.
Internal dosimetry study of [Rb-82]Cl using a long axial field-of-view PET/CT
Our study suggests that the radiation dose associated with [Rb-82]Cl PET/CT can be assessed by means of dynamic LAFOV PET and that it is lower compared to literature values.
Anatomically guided reconstruction improves lesion quantitation and detectability in bone SPECT/CT
Bone single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging suffers from poor spatial resolution, but the image quality can be improved during SPECT reconstruction by using anatomical information derived from CT imaging.
Brochures
Theranostics Brochure
Brochure dedicated to the advanced tools for Theranostics and Therapies within the Hermia software.
Hermia product overview
Product overview of Hermia, a state-of-the-art software suite that supports all clinical scenarios in NM/MI on all cameras.
Future Liver Remnant Function
Ensure the best outcome for your patients undergoing major liver resection
White papers
Hermia SPECT Reconstruction
The quality of SPECT imaging is reduced by photon attenuation, resolution loss due to collimator-detector blur, photon scatter, and noise. All these factors limit both the visual quality and quantitative power of SPECT images. Hermia SPECT Reconstruction provides methods to compensate for the effects of the aforementioned four factors by modelling them in iterative reconstruction.
Hermia Advanced Bone SPECT Reconstruction
Our easy-to-use software enables precise determination of reconstruction parameters, and we are proud to be able to offer two Bayesian reconstruction algorithms to optimise your bone SPECT/CT images: AMAP-Smooth and AMAP-RDP.
